TNG-908 is a small molecule commercialized by Tango Therapeutics, with a leading Phase II program in Soft Tissue Sarcoma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of TNG-908’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for TNG-908 is expected to reach an annual total of $490 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
TNG-908 Overview
TNG-908 is under development for the treatment of MTAP-deleted cancers like mesothelioma, squamous and non squamous non-small cell lung cancer, bladder cancer, glioblastoma multiforme, malignant glioma, colon cancer, pancreatic ductal adenocarcinoma and soft tissue sarcoma. It is administered through oral route. It acts by targeting the protein arginine methyltransferase 5 (PRMT5) enzyme.
It was under development for the treatment of MTAP-deleted cancers like cholangiocarcinoma, malignant peripheral nerve sheath tumor (MPNST).
Tango Therapeutics Overview
Tango Therapeutics is a biotechnology company that focuses on developing precision medicines for cancer treatment. Its main activities involve leveraging synthetic lethality and CRISPR-based functional genomics to discover and validate novel cancer therapy targets. The company’s products include synthetic lethal inhibitors such as TNG908 and TNG462, that target specific genetic alterations in cancer cells. Tango Therapeutics’ products are designed for patients with genetically defined subsets of cancers. Tango Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$36.5 million for the fiscal year ended December 2023 (FY2023), an increase of 46.9% over FY2022. The operating loss of the company was US$114.2 million in FY2023, compared to an operating loss of US$111.1 million in FY2022. The net loss of the company was US$101.7 million in FY2023, compared to a net loss of US$108.2 million in FY2022.
The company reported revenues of US$19.9 million for the second quarter ended June 2024, compared to a revenue of US$6.5 million the previous quarter.
For a complete picture of TNG-908’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
